Dr. Branagan on Novel Induction Therapies With Transplant in Myeloma

Andrew Branagan, MD, discusses novel induction therapies being used with transplant to improve outcomes in patients with multiple myeloma.

Andrew Branagan, MD, a medical oncologist at Massachusetts General Hospital Cancer Center,discusses novel induction therapies being used with transplant to improve outcomes in patients with multiple myeloma.

The field of multiple myeloma has come a long way with regard to induction therapies, Branagan explains. While very good partial remission (VGPR) rates were previously less than 50%, they are now observed in two-thirds of patients. Some data have indicated that up to 100% of patients achieve VGPR with certain regimens, making it difficult to decide which approach to use. 

Currently, the standard regimen is the combination of lenalidomide (Revlimid), bortezomib (Velcade), and daratumumab (Darzalex). Some growing data suggest that current standards will probably change in the near future, concludes Branagan.

Related Videos
Amandeep Godara, MBBS
Eunice Wang, MD
Yvonne Chao, MD, PhD
Ruth M. O’Regan, MD, professor, chair, Charles Ayrault Dewey Professorship of Medicine, Department of Medicine, the University of Rochester, physician-in-chief, Strong Memorial Hospital, associate director, Education and Mentoring, the Wilmot Cancer Institute at University of Rochester,
Timothy Burns, MD, PhD, associate professor of medicine, associate program director, Research, associate program director, Hematology/Oncology Fellowship Program, Department of Medicine, Division of Hematology-Oncology, UPMC Hillman Cancer Center
Sapna Patel, BA, MD
Brian Henick, MD
R. Lor Randall, MD, FACS
Edward B. Garon, MD, MS, professor of medicine, Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine, the University of California, Los Angeles (UCLA), UCLA Health
Matthew Brunner, MD, assistant professor, hematologic specialist, medical oncology, and palliative care, Department of Medicine, University of Wisconsin Carbone Cancer Center
Related Content